Hubli railway division

NMD Pharma announces poster and oral presentations on skeletal muscle targeted ClC-1 therapy at two leading neuromuscular disease conferences

Retrieved on: 
Friday, March 1, 2024

ClC-1 is a chloride ion channel specifically expressed in skeletal muscle cells that normally dampens muscle fiber excitability and is involved in regulating muscle fiber excitability during exercise.

Key Points: 
  • ClC-1 is a chloride ion channel specifically expressed in skeletal muscle cells that normally dampens muscle fiber excitability and is involved in regulating muscle fiber excitability during exercise.
  • ClC-1 inhibition could be a possible mechanism to improve muscle fiber activation to address muscle weakness and fatigue in neuromuscular diseases.
  • Details of NMD Pharma’s poster presentations are below:
    The 4th Scientific International Congress on SMA is taking place in Ghent, Belgium, from 14-16 March.
  • : NMD Pharma be presenting one poster and one oral presentation at the congress.

Revance Receives Permanent J-Code for DAXXIFY® and Announces Publication of DAXXIFY Pivotal Study (ASPEN-1) Results in Neurology®

Retrieved on: 
Friday, February 2, 2024

The company also announced today the publication of results from the ASPEN-1 Pivotal Phase 3 study in Neurology®, the medical journal of the American Academy of Neurology.

Key Points: 
  • The company also announced today the publication of results from the ASPEN-1 Pivotal Phase 3 study in Neurology®, the medical journal of the American Academy of Neurology.
  • “Importantly, the real-world clinical results of DAXXIFY from the patients I have injected so far in PrevU, including safety, efficacy and duration, are in-line with those seen in the ASPEN-1 study.
  • DAXXIFY® is not approved for the treatment of spasticity or any conditions other than cervical dystonia and glabellar lines.
  • To report side effects associated with DAXXIFY®, please visit safety.revance.com, or call 1-877-373-8669.

Revance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial Outlook

Retrieved on: 
Monday, January 8, 2024

Revance Therapeutics , Inc. (NASDAQ:RVNC) today provided a corporate update as well as preliminary unaudited fourth quarter and full year 2023 financial results, 2024 guidance and financial outlook.

Key Points: 
  • Revance Therapeutics , Inc. (NASDAQ:RVNC) today provided a corporate update as well as preliminary unaudited fourth quarter and full year 2023 financial results, 2024 guidance and financial outlook.
  • We wish Dustin the best in his new endeavors.”
    Corporate Updates and Preliminary Q4 and FY 2023 Financial Results:
    Revance expects Q4 2023 preliminary unaudited DAXXIFY revenue to be between $23.5 million and $24.5 million.
  • Full year 2023 preliminary unaudited DAXXIFY revenue is expected to be between $83.5 million and $84.5 million.
  • Revance expects preliminary unaudited fourth quarter 2023 RHA Collection revenue to be between $34 million and $35 million, and full year preliminary unaudited 2023 RHA Collection revenue to be between $128 million and $129 million.

Global Claudin 18.2 Targeted Therapy Market Opportunity Report 2023-2028: 60 Drugs in Clinical Trial, Insight On Technical & Clinical Development Platforms, Breakdown by Company, Indication & Phase - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 21, 2023

The "Global Claudin 18.2 Targeted Therapy Market Opportunity & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Claudin 18.2 Targeted Therapy Market Opportunity & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering.
  • Small pharmaceutical companies working on CLDN18-targeting therapies are also becoming more visible in the pharmaceutical market.
  • Therefore, CLDN18 and its variant CLDN18.2 are a ray of hope in the pharmaceutical industry, especially cancer therapy.
  • Claudin 18.2 Targeted Drugs In Clinical Trials: > 60 Drugs
    Global Claudin 18.2 Drugs Clinical Trials By Company, Indication & Phase
    Claudin 18.2 Targeted Therapy Development Approaches: CAR T Cell Therapy, Bispecific Antibodies, Antibody Drug Conjugates

DAXXIFY® Becomes First Facial Injectable to be Named to TIME’s Best Inventions

Retrieved on: 
Thursday, October 26, 2023

TIME® has unveiled its annual Best Inventions list , which features 200 of the year’s best innovations that are making the world better, smarter, and more enjoyable.

Key Points: 
  • TIME® has unveiled its annual Best Inventions list , which features 200 of the year’s best innovations that are making the world better, smarter, and more enjoyable.
  • The entrants were then evaluated against a number of key factors, including originality, efficacy, ambition, and impact.
  • DAXXIFY® is not approved for the treatment of spasticity or any conditions other than cervical dystonia and glabellar lines.
  • You may also report side effects to the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch .

U.S. FDA Approves First Therapeutic Indication for Revance’s DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia

Retrieved on: 
Monday, August 14, 2023

Peter McAllister, M.D., ASPEN investigator and co-founder and medical director of the New England Institute for Neurology and Headache, commented: “As an ASPEN investigator, I am excited to see the approval of a new treatment option to address symptom reemergence prior to retreatment, a common issue for cervical dystonia patients. Currently, patients experience painful and life-limiting symptom recurrence as early as eight to 10 weeks in clinical practice but cannot be re-treated until 12 weeks. DAXXIFY® is the first long-acting neuromodulator that has the potential to address this significant unmet need -- demonstrating durable symptom relief between treatment cycles and providing the opportunity to extend treatment intervals.”

Key Points: 
  • In 2017, the U.S. FDA granted orphan drug designation to DAXXIFY® for the treatment of cervical dystonia in adults.
  • Further, we believe FDA approval represents a significant advancement in the treatment of cervical dystonia,” said Chief Executive Officer Mark J. Foley.
  • “DAXXIFY’s differentiated efficacy, duration and safety profile can help physicians deliver long-lasting symptom relief to patients suffering from cervical dystonia, while also helping payers address the total cost of care for this population.
  • DAXXIFY® is not approved for the treatment of spasticity or any conditions other than cervical dystonia and glabellar lines.

GENIXUS Announces Launch of KinetiXTM Rocuronium Bromide Injection 5mL & 10mL Ready-to-Administer Syringes

Retrieved on: 
Thursday, August 3, 2023

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230803139911/en/
    KinetiX Propofol & Rocuronium Bromide Injection RTA Syringes.
  • KinetiX Rocuronium Bromide Injection possesses several key attributes inherent in the KinetiX platform:
    GENIXUS' Chief Commercial Officer (CCO), Seth Coombs , emphasized the company's determination to accelerate the launch of Rocuronium Bromide Injection to address the ongoing, and expected worsening, of shortages in the US market.
  • If rocuronium bromide injection is administered via the same infusion line that is also used for other drugs, it is important that this infusion line is adequately flushed between administration of rocuronium bromide injection and drugs for which incompatibility with rocuronium bromide injection has been demonstrated or for which compatibility with rocuronium bromide injection has not been established.
  • Rocuronium bromide is contraindicated in patients known to have hypersensitivity (e.g., anaphylaxis) to rocuronium bromide or other neuromuscular blocking agents.

Annual Congress 2023 of the European Academy of Allergy and Clinical Immunology: Study Shows Air Pollution's Impact on Airways of Early-Career Elite Athletes

Retrieved on: 
Friday, June 16, 2023

HAMBURG, Germany, June 16, 2023 /PRNewswire/ -- A recent study conducted in Belgium has revealed the potential effects of air pollution on the airways of early-career elite athletes.

Key Points: 
  • HAMBURG, Germany, June 16, 2023 /PRNewswire/ -- A recent study conducted in Belgium has revealed the potential effects of air pollution on the airways of early-career elite athletes.
  • The abstract was presented on 11th June at the Annual Congress in Hamburg organized by the European Academy of Allergy & Clinical Immunology (EAACI).
  • The research focused on early-career elite athletes aged 12 to 18 years and aimed to investigate the exposure and impact of air pollutants on their airways.
  • Janne Goossens, the PhD researcher of KU Leuven, commented, "Our study highlights the potential impact of air pollution on the airways of early-career elite athletes.

Antengene Announces Claudin 18.2 Antibody-Drug Conjugate ATG-022 Granted Orphan Drug Designations by the U.S. FDA for the Treatment of Gastric and Pancreatic Cancers

Retrieved on: 
Tuesday, May 23, 2023

To date, Antengene has received 3 ODDs from the FDA for two of its in-house products.

Key Points: 
  • To date, Antengene has received 3 ODDs from the FDA for two of its in-house products.
  • Orphan Drugs, also known as Rare Disease Drugs, refers to pharmaceutical products developed for the prevention, diagnosis, and treatment of rare diseases or conditions.
  • The Claudin 18.2 isoform is overexpressed in various primary malignant tumors including gastric, esophageal and pancreatic cancers.
  • Moving forward, Antengene will work closely with regulators and clinical investigators to advance the CLINCH trial and fully assess ATG-022's therapeutic potential for solid tumors."

Revance to Present New Data on DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia at the Association of Academic Physiatrists Annual Meeting

Retrieved on: 
Thursday, February 23, 2023

(RVNC) today announced that new data on DAXXIFY ® will be presented at the annual meeting of Association of Academic Physiatrists (AAP), taking place in Anaheim, California, February 21-24, 2023.

Key Points: 
  • (RVNC) today announced that new data on DAXXIFY ® will be presented at the annual meeting of Association of Academic Physiatrists (AAP), taking place in Anaheim, California, February 21-24, 2023.
  • The supplemental biologics license agreement for DAXXIFY® for the treatment of cervical dystonia is currently under regulatory review with the Food and Drug Administration.
  • The findings reinforce the extended duration of efficacy and favorable safety profile of DAXXIFY®.
  • Dysphagia rates (difficulty swallowing) were low (2.7% for ASPEN-1 and 4.2% for ASPEN-OLS), further supporting DAXXIFY’s safety profile.